JERSEY CITY, N.J., May 28, 2015 – TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced that it is adding another clinical trial sponsor to its growing client list for the PharmaCM clinical trial disclosure platform. The latest sponsor to join TrialScope’s client list selected the PharmaCM platform to replace an existing commercial product that had been previously implemented.
The new account represents continued growth for TrialScope since the company acquired the PharmaCM platform in June 2014. Currently, over 8,000 users around the world are managing almost 30,000 clinical trial registrations using the PharmaCM platform.
Mike Forgash, CEO, TrialScope, commented, “The TrialScope team looks forward to working with a new sponsor team and adding to its growing roster of satisfied clients. Our expanding customer base is a testament to the simplicity, efficiency and overall value that our zero-footprint solutions bring to complex clinical trial disclosure processes. Our team’s strong reputation for depth of knowledge and breadth of experience is attractive to clients of all sizes who are looking to stay ahead of the curve regarding ever-changing global regulatory requirements and need a disclosure-driven solution as opposed to simply a technology. This is especially important as emerging regulations (such as the EU Clinical Trials Regulation) add complexity to global trial disclosure processes.”
Thomas Wicks, Chief Strategy Officer, noted that the TrialScope team is leveraging its “Rapid Path to Compliance,” a proven engagement methodology based on collaboration and compliance and focused on quickly implementing the PharmaCM platform and decreasing the client’s time to productivity. He added, “As new clients come aboard, we have a unique chance to partner with them to transform their business practices and lower risks of non-compliance. Our practical knowledge is baked into our Rapid Path to Compliance methodology so clients get the combined benefits of our experience and our technology platform to simplify compliance and increase productivity.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.